{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-003483","form_type":"8-K","ticker":"AGEN","cik":"0001098972","company_name":"AGENUS INC","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:59.736004+00:00","generated_at":"2026-06-25T21:26:19.450567+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agenus Q1 2022 net loss $51M; cash $263M; botensilimab to Phase 2; Gilead $5M milestone","bullets":["Net loss of $51M ($0.19/share) vs $54M ($0.27/share) YoY; revenue $26M (up from $12M).","Cash and short-term investments $263M, down from $307M at Dec 31, 2021; cash used in ops $52M.","Botensilimab advancing to Phase 2 trials in colorectal, melanoma, pancreatic cancers; data in Q3 2022.","AGEN1571 (ILT2) Phase 1 to start; AGEN2373 milestone of $5M from Gilead (up to $570M potential).","Cost containment measures initiated to reduce operating expenses in coming quarters."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-003483","json":"https://secwatch.observer/filing/0001171843-22-003483.json","markdown":"https://secwatch.observer/filing/0001171843-22-003483.md","text":"https://secwatch.observer/filing/0001171843-22-003483.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/0001171843-22-003483-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1098972/000117184322003483/f8k_051022.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:26:19.450567+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}